ArticleBMC research notes2025
High IL-8 plasma levels at baseline are predictive of poor overall survival in breast cancer patients receiving chemotherapy.
Article in BMC research notes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- CXCL8 Promotes the Progression of Vulvar Squamous Cell Carcinoma and Serves as a Potential Prognostic Biomarker.International journal of women's health · 2026Article
- Efficacy and survival outcomes of bevacizumab plus minocycline for glioblastoma.American journal of translational research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveOur earlier work reported the association of inflammatory biomarker with a reduced breast cancer chemotherapy relative dose intensity (RDI) resulting in an unfavourable survival outcome. This current study aimed to assess the prognostic role of inflammatory biomarkers in patients with breast cancer, particularly Interleukin-8 (IL-8).
resultsThis study included 168 breast cancer patients. The median follow-up was 24.3 (range 3-77) months. Kaplan-Meier and log-rank test showed that the 3-year overall survival (OS) in patients with high IL-8 plasma level (> 6.88pg/mL) were significantly lower than those with low level (≤ 6.88pg/mL) (59.6% vs. 76.4%, P = 0.049). Multivariate Cox regression analysis adjusted with stage and HER2 showed high IL-8 as prognostic factor for poor OS (HR 1.70, 95%CI [1.01-2.84], P = 0.044). Multivariate comparisons for disease-free survival (DFS) and progression-free survival (PFS) revealed none of the investigated inflammatory biomarkers having prognostic significance. More patients with older age and stage IV disease had a high IL-8 level than their counterparts (54 vs. 51 years, P = 0.020 and 61% vs. 39%, P = 0.012). High IL-8 level may serve as potential prognostic biomarker in the clinical setting in order to deliver more personalized care and strategy toward better outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.